Ethan O. Perlstein received a PhD in 2006 from Harvard University (Department of Molecular and Cell Biology) while working in the laboratory of Professor Stuart Schreiber. He completed an independent postdoctoral fellowship at the Lewis-Sigler Institute at Princeton University from 2007 to 2012. Since its founding in 2014, he is CEO of Perlara PBC, the first biotech PBC partnering with highly motivated families to develop treatments and cures for genetic diseases. Perlara’s first joint venture Maggie’s Pearl is the commercial sponsor of Phase 3 trial of epalrestat for the treatment of PMM2-CDG at the Mayo Clinic.